{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T16:05:53Z","timestamp":1780761953655,"version":"3.54.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41391-025-00983-8","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:16:43Z","timestamp":1747898203000},"page":"985-988","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Abiraterone for \u201cSTAMPEDE-Like\u201d cohort of high-risk prostate cancer in the PSMA-PET era: too much, too early?"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6011-9319","authenticated-orcid":false,"given":"Vedang","family":"Murthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asesh","family":"Samanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8878-7914","authenticated-orcid":false,"given":"Priyamvada","family":"Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagan","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"983_CR1","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf (accessed March 18, 2023)."},{"key":"983_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399:447\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(21)02437-5.","journal-title":"Lancet"},{"key":"983_CR3","doi-asserted-by":"crossref","unstructured":"Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND et al. Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2025;87:157\u2013216.","DOI":"10.1016\/j.eururo.2024.09.017"},{"key":"983_CR4","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"Lancet"},{"key":"983_CR5","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer LGW, Groen VH, Pos FJ, Haustermans K, Monninkhof EM, Smeenk RJ, et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol. 2021;39:787\u201396. https:\/\/doi.org\/10.1200\/JCO.20.02873.","journal-title":"J Clin Oncol"},{"key":"983_CR6","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1200\/JCO.20.03282","volume":"39","author":"V Murthy","year":"2021","unstructured":"Murthy V, Maitre P, Kannan S, Panigrahi G, Krishnatry R, Bakshi G, et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol. 2021;39:1234\u201342. https:\/\/doi.org\/10.1200\/JCO.20.03282.","journal-title":"J Clin Oncol"},{"key":"983_CR7","doi-asserted-by":"publisher","first-page":"e180039","DOI":"10.1001\/jamaoncol.2018.0039","volume":"4","author":"JM Michalski","year":"2018","unstructured":"Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial. JAMA Oncol. 2018;4:e180039.","journal-title":"JAMA Oncol"},{"key":"983_CR8","doi-asserted-by":"publisher","unstructured":"Maitre P, Maheshwari G, Sarkar J, Singh P, Kannan S, Dutta S, et al. Late urinary toxicity and QOL with pelvic radiotherapy for high-risk prostate cancer: Dose-effect relations in the POP-RT randomized phase III trial. Int J Radiat Oncol. 2024. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.03.023.","DOI":"10.1016\/j.ijrobp.2024.03.023"},{"key":"983_CR9","doi-asserted-by":"publisher","unstructured":"Ravi P, Xie W, Buyse M, Halabi S, Kantoff PW, Sartor O, et al. Refining risk stratification of high-risk and locoregional prostate cancer: a pooled analysis of randomized trials. Eur Urol. 2024. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.038.","DOI":"10.1016\/j.eururo.2024.04.038"},{"key":"983_CR10","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403:1683\u2013722. https:\/\/doi.org\/10.1016\/S0140-6736(24)00651-2.","journal-title":"Lancet"},{"key":"983_CR11","doi-asserted-by":"publisher","first-page":"e0269192","DOI":"10.1371\/journal.pone.0269192","volume":"17","author":"CS Clarke","year":"2022","unstructured":"Clarke CS, Hunter RM, Gabrio A, Brawley CD, Ingleby FC, Dearnaley DP, et al. Cost-utility analysis of adding abiraterone acetate plus prednisone\/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: lifetime decision model based on STAMPEDE trial data. PLOS ONE. 2022;17:e0269192. https:\/\/doi.org\/10.1371\/journal.pone.0269192.","journal-title":"PLOS ONE"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00983-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00983-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00983-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T02:48:11Z","timestamp":1764038891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00983-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["983"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-00983-8","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"7 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"We confirm that all methods were performed in accordance with the relevant guidelines and regulations. Ethical approval was taken from the Institutional Ethical Committee of Tata Memorial Hospital, Mumbai (IEC no. 900936). No informed consent\u00a0as Ethics Committee granted wavier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}